NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Nurix Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026
$24.93+0.51 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $2.90B
- P/E (TTM)
- 10.8
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-340.2%+24.5 pts over 5 years
Net margin
-314.9%−72.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +54.0% | +29.5% | +36.3% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -37.2% | -49.6% | |
| Return on assets | – | -19.6% | -39.0% | |
| Current ratio | – | 6.70 | 7.02 | |
| Capex to revenue | – | 25.5% | 16.7% | |
| Diluted shares | – | 16M | 87M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Nurix Therapeutics generated $747.59M from operations and spent $49.58M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$747.59M
Used
$49.58M
Capital expenditure$49.58M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-314.9%
×Asset turnover0.12×
×Equity multiplier1.27×
=Return on equity, FY2025-49.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -314.9% | 0.12× | 1.27× | -49.6% |
| FY2024 | -354.9% | 0.11× | 1.41× | -53.2% |
| FY2023 | -187.0% | 0.20× | 1.53× | -57.1% |
| FY2022 | -466.9% | 0.09× | 1.38× | -55.8% |
| FY2021 | -393.9% | 0.07× | 1.38× | -37.1% |
| FY2020 | -242.7% | 0.08× | 1.89× | -37.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$264.46M
- Cash generatingOperating cash flow above zero-$249.47M
- Return on assets improvedROA up on the prior year-54.4% → -39.5%
- Earnings backed by cashOperating cash flow above net income-$249.47M vs -$264.46M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.46 → 7.02
- No dilutionShare count did not rise67M → 87M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.15 → 0.13